Phaseline

Companies › Actinogen Medical

Actinogen Medical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Xanamem
11β-hydroxysteroid dehydrogenase type 1 inhibitor
CYP11B1Phase 2Dementia ModerateFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06125951XanamemPhase 2Dementia ModerateNeurologyFeb 2028

Targets

CYP11B1 (1)

Companies with the same targets

RECORDATI GROUP H. Lundbeck

Companies built like this

Aptinyx Neuron23 Bial R&D Investments SHINKEI Therapeutics NeuroTherapia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.